Skip to main content

Advertisement

SpringerLink
Log in

Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

The recent WHO classification of breast cancer (2019) categorizes breast carcinoma with neuroendocrine (NE) differentiation into three morphologically distinct subtypes: well-differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine carcinoma (NEC), and invasive breast carcinoma, no special type with neuroendocrine differentiation (IBC-NST-NE). Data regarding the prognostic significance of neuroendocrine differentiation are conflicting and an association, if any, between p53 mutation and neuroendocrine differentiation is largely unknown.

Methods

We examined p53 expression and other clinicopathologic characteristics in three types of invasive breast carcinoma with NE differentiation in a cohort of sixty-three patients, including 45 IBC-NST with NE differentiation, 10 NETs, and 8 NECs.

Results

No significant difference of clinicopathologic feature was observed between IBC-NST with NE differentiation and NET, but NECs showed significantly lower expressions of hormone receptors, more mutated p53, and higher frequency of distant metastases than IBC-NST with NE differentiation and NETs.

Conclusion

NECs of the breast are genetically and clinically different from IBC-NST-NEs and NETs of the breast.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tavassoli F, Schnitt S, Hoefler H (2003) Intraductal proliferative lesions. In: Tavassoli F, Devilee P (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC press, Lyon

    Google Scholar 

  2. Feyrter F (1963) On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (gelatinosum) mammae (in German). Frankf Z Pathol 73:24–39

    CAS  PubMed  Google Scholar 

  3. Miremadi A, Pinder S, Lee A et al (2002) Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 40(3):215–222

    Article  CAS  PubMed  Google Scholar 

  4. Gallo M, Campione S, Di Vito V et al (2021) Primary neuroendocrine neoplasms of the breast: still open issues. Front Endocrinol. https://doi.org/10.3389/fendo.2020.610230

    Article  Google Scholar 

  5. Tan PH, Ellis I, Allison K et al (2020) The 2019 World Health Organization classification of tumours of the breast. Histopathology. https://doi.org/10.1111/his.14091

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rindi G, Klimstra DS, Abedi-Ardekani B et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31(12):1770–1786

    Article  PubMed  PubMed Central  Google Scholar 

  7. Pareja F, D’Alfonso TM (2020) Neuroendocrine neoplasms of the breast: a review focused on the updated World Health Organization (WHO) morphologic classification. Breast J 26(6):1160–1167

    Article  PubMed  Google Scholar 

  8. Yang L, Roy M, Lin H et al (2021) Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Res Treat 186(2):403–415

    Article  PubMed  Google Scholar 

  9. Biganzoli E, Coradini D, Ambrogi F et al (2011) p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol 41(2):172–179

    Article  PubMed  Google Scholar 

  10. Bean GR, Najjar S, Shin SJ et al (2022) Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast. Mod Pathol 35(10):1349–1361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y (2014) Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer 14:147

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rovera F, Masciocchi P, Coglitore A et al (2008) Neuroendocrine carcinomas of the breast. Int J Surg 6:S113–S115

    Article  PubMed  Google Scholar 

  13. Lavigne M, Menet E, Tille J-C et al (2018) Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol 31(1):68–82

    Article  CAS  PubMed  Google Scholar 

  14. Tian Z, Wei B, Tang F et al (2011) Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 42(8):1169–1177

    Article  CAS  PubMed  Google Scholar 

  15. Zekioglu O, Ylz Erhan, Çiriş M, Bayramoglu H (2003) Neuroendocrine differentiated carcinomas of the breast: a distinct entity. Breast. 12(4):251–257

    Article  PubMed  Google Scholar 

  16. Lopez-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernado L, Menendez JA (2008) Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 20(6):1369–1374

    PubMed  Google Scholar 

  17. Lavigne M, Menet E, Tille J-C et al (2018) Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol 31(1):68–82

    Article  CAS  PubMed  Google Scholar 

  18. Koboldt D, Fulton R, McLellan M et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70

    Article  CAS  Google Scholar 

  19. Li J-p, Zhang X-m, Zhang Z, Zheng L-h, Jindal S, Liu Y-j (2019) Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine. https://doi.org/10.1097/MD.0000000000015449

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4(2):1–7

    Article  Google Scholar 

  21. Ang D, Ballard M, Beadling C et al (2015) Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets. Appl Immunohistochem Mol Morphol 23(2):97–103

    Article  CAS  PubMed  Google Scholar 

  22. Marchiò C, Geyer FC, Ng CK et al (2017) The genetic landscape of breast carcinomas with neuroendocrine differentiation. J Pathol 241(3):405–419

    Article  PubMed  Google Scholar 

  23. Wei B, Ding T, Xing Y et al (2010) Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer 116(19):4463–4473

    Article  PubMed  Google Scholar 

  24. Wei Y, Ke X, Yu J et al (2022) Clinical and genomic analyses of neuroendocrine neoplasms of the breast. Mod Pathol 35(4):495–505

    Article  CAS  PubMed  Google Scholar 

  25. Lakhani SR, Ellis IO, Schnitt S, Tan PH, van de Vijver M (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon

    Google Scholar 

  26. Tang F, Wei B, Tian Z et al (2011) Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106–115

    Article  PubMed  Google Scholar 

  27. Makuuchi R, Terashima M, Kusuhara M et al (2017) Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. Biomed Res 38(1):19–27

    Article  CAS  PubMed  Google Scholar 

  28. Pizzi S, Azzoni C, Bassi D, Bottarelli L, Milione M, Bordi C (2003) Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer Interdiscip Intern J Am Cancer Soc 98(6):1273–1282

    CAS  Google Scholar 

  29. Furlan D, Cerutti R, Uccella S et al (2004) Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 10(3):947–957

    Article  CAS  PubMed  Google Scholar 

  30. Sahnane N, Furlan D, Monti M et al (2015) Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer 22(1):35–45

    Article  CAS  PubMed  Google Scholar 

  31. Chan AO-O, Kim SG, Bedeir A, Issa J-P, Hamilton SR, Rashid A (2003) CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22(6):924–934

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Pathology, The Ohio State University Wexner Medical Center, 410 W. 10th Ave, Columbus, OH, 43210, USA

    Saba Shafi, Yan Hu, Anil V. Parwani & Zaibo Li

  2. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Qingqing Ding

Authors
  1. Saba Shafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anil V. Parwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qingqing Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zaibo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study design: All. Data collection: SS, YH, AVP, QD, and ZL. Data analysis: SS, YH, QD, and ZL. Statistical oversight: SS. Manuscript preparation: SS, YH, AVP, QD, and ZL. Manuscript approval: All.

Corresponding author

Correspondence to Zaibo Li.

Ethics declarations

Conflict of interest

The authors declare that they have no financial relationship to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual patients included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shafi, S., Hu, Y., Parwani, A.V. et al. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center. Breast Cancer Res Treat 196, 463–469 (2022). https://doi.org/10.1007/s10549-022-06766-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-022-06766-2

Keywords

Search

Navigation